Morphological response and tumor shrinkage as predictive factors in metastatic colorectal cancer treated with first-line capecitabine, oxaliplatin, and bevacizumab-Reference-Cited by-同舟云学术

Morphological response and tumor shrinkage as predictive factors in metastatic colorectal cancer treated with first-line capecitabine, oxaliplatin, and bevacizumab

Published:2023-06-22 Issue:9 Volume:28 Page:1191-1199
ISSN:1341-9625
Container-title:International Journal of Clinical Oncology
language:en
Short-container-title:Int J Clin Oncol

Author:

Nagaoka Tomoyuki,Osumi Hiroki,Ueno Teruko,Ooki Akira,Wakatsuki Takeru,Nakayama Izuma,Ogura Mariko,Takahari Daisuke,Chin Keisho,Matsueda Kiyoshi,Yamaguchi Kensei,Shinozaki Eiji^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Hematology,General Medicine,Surgery

Link

https://link.springer.com/content/pdf/10.1007/s10147-023-02370-6.pdf

Reference24 articles.

1. Bray F, Ferlay J, Soerjomataram I et al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424. https://doi.org/10.3322/caac.21492

2. Van Cutsem E, Cervantes A, Adam R et al (2016) ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 27:1386–1422. https://doi.org/10.1093/annonc/mdw235

3. Stebbing J, Singh Wasan HS (2019) Decoding metastatic colorectal cancer to improve clinical decision making. J Clin Oncol 37:1847–1850. https://doi.org/10.1200/JCO.19.01185

4. Siegel R, Desantis C, Jemal A (2014) Colorectal cancer statistics, 2014. CA Cancer J Clin 64:104–117. https://doi.org/10.3322/caac.21220

5. Cassidy J, Clarke S, Díaz-Rubio E et al (2008) Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 26:2006–2012. https://doi.org/10.1200/JCO.2007.14.9898